Randomized Trialhigh evidence
Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy).
American journal of respiratory and critical care medicine·July 1, 2026·PMID 42148495
Why it mattersMany OSA patients cannot use PAP, leaving a large treatment gap. AD109 offers a novel oral pharmacotherapy targeting neuromuscular dysfunction, with clinically meaningful AHI reduction and a tolerable safety profile, expanding options for non-PAP candidates.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled